Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication
Key Highlights
- ➤Hong Kong publishes patent application for Clearmind’s PTSD-focused psychedelic compounds
- ➤Clearmind holds exclusive global development, manufacturing, and commercialization rights
- ➤Clearmind’s portfolio includes 19 patent families and 32 granted patents
- ➤PTSD therapeutics market valued at approximately $19 billion in 2025
- ➤GlobalData projects PTSD pharmaceutical market growth to $5.5 billion by 2034
Vancouver, Canada, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a Hong Kong patent application covering innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (“PTSD”) and other mental health disorders.
The patent application is part of the Company's exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). The compounds were invented by Professors Ahmed Masaewa, Rami Yaka, and Avi Priel of the Hebrew University. Under the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize the novel compounds.
Get started
Create a free account to read the full story.
